

December 7, 2000

Müller-Boré &amp; Partner

Application No.: PCT/EP99/06433

Applicant: Biopharm Gesellschaft zur biotechnologischen Entwicklung und zum Vertrieb von Pharmaka mbH

"Use of TGF-Inhibitors for treating cerebral disorders"

Our Ref: B 1957 - py / js

## Claims

1. Use of a compound capable of inhibiting the biological activity of TGF- $\beta$  on predamaged neurons, for the preparation of a medicament for treating cerebral disorders.
2. Use according to claim 1, wherein said compound is an antibody or an antagonist directed to TGF- $\beta$ .
3. Use according to claim 1 or 2, wherein said disorder is a peripheral and/or CNS-disorder.
4. Use according to claim 3, wherein said disorder is a cerebral ischemia or a neurodegenerative disorder.
5. A pharmaceutical composition containing, in pharmaceutically effective amounts, a compound capable of inhibiting the biological activity of TGF- $\beta$  on predamaged neurons, and a second compound for disintegrating blood clots.
6. The pharmaceutical composition according to claim 5 further containing a pharmaceutically acceptable carrier and/or diluent.
7. The pharmaceutical composition according to claim 5 or 6, wherein said compound is an antibody directed to TGF- $\beta$  or a compound having the binding site of a TGF- $\beta$  receptor.

8. The pharmaceutical composition according to anyone of claims 5 to 7, wherein said second compound is selected from the group consisting of urokinase and tissue plasminogen activator.

ms

add B2

[illegible]